2026 IBK Changgong — K-Biotech in Germany
Program Overview#
Companies joining the 2026 IBK Changgong Global (Germany) Accelerating Program — K-Biotech in Germany, where 123factory serves as an operating partner, are gathered here.
The companies below are Korean bio and healthcare startups entering the European market through Germany. Through the program they connect with German research institutions, bio and healthcare clusters, pharmaceutical companies, and hospitals for joint research and business partnerships, with an on-site program in Germany in September 2026. Key partners include KIST Europe, Helmholtz, PharmaScienceHub (PSH), Fraunhofer, the BioRN cluster, and the 5-HT innovation hub.
Participating Companies#
The Korean bio and healthcare startups below are looking for research and business partners in Germany and across Europe. If you work at a research institute, cluster, pharmaceutical company, or hospital, each profile shows the company’s technology, product maturity, and references, along with the kind of collaboration it is open to — joint research, clinical validation, PoC, distribution, or licensing.
Request a meeting
Tell us who you'd like to meet and we'll get back to you.
Companies in this program
5 companies
Machine learning-driven AAV capsid engineering platform with in-house CMC manufacturing for tissue-specific gene therapy delivery.
An iPad-based medical device that uses AI to analyze how a person walks from a single camera, with no body sensors.
AI blood test for early lung cancer screening that combines multiple serum protein biomarkers with machine learning.
A biotech company developing a natural, plant-based pill (BCD101) that the body absorbs well, aimed at treating painful nighttime leg cramps.
A single-chip platform that uses a magnetic field to pull cancer cells out of a blood sample, then reads their DNA for cancer diagnostics.
No companies match the selected industry.